Aprea Therapeutics Inc

Insider buying in Aprea Therapeutics signals confidence amid a steep plunge, offering potential upside through new shares and warrants—watch for future clinical data.

CEO Gilad Oren’s recent buy‑the‑dip move on Aprea Therapeutics shows top‑level confidence in the company’s mutant‑p53 drug pipeline, but investors must weigh the high‑risk, cash‑burning biotech backdrop against potential upside catalysts.